Fulgent Genetics, Inc. FLGT Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Business | ||||||
| Laboratory Services | $71.05M-3.3% | $83.03M+8.9% | $83.93M+17.0% | $81.8M+15.2% | $73.46M+13.9% | |
| Therapeutic Development | $87K— | $309K— | $138K— | $0— | $0— | |
| Operating Income by Business | ||||||
| Laboratory Services | -$15.22M-407% | -$4.18M— | $2.49M+814% | -$2.81M-417% | -$3M+36.4% | |
| Therapeutic Development | -$4.46M-4.8% | -$4.72M-6.2% | -$6M-57.2% | -$4.88M-2.9% | -$4.25M-19.3% | |
| Cost Of Revenue by Business | ||||||
| Laboratory Services | $48.18M+11.2% | $49.14M+15.6% | $46.86M+8.9% | $45.63M+7.3% | $43.34M+7.3% | |
| Therapeutic Development | $8K— | $5K— | $0— | $0— | $0— | |
| Interest Expense Nonoperating by Business | ||||||
| Laboratory Services | $17K+21.4% | $16K— | $28K+100% | $17K-32.0% | $14K+106% | |
| Therapeutic Development | $0— | $0— | $0— | $0— | $0— | |
| Finite Lived Intangible Assets Gross by Business | ||||||
| Laboratory Services | $105.15M+26.5% | $83.14M+0.1% | $83.12M0.0% | $83.11M0.0% | $83.09M0.0% | |
| Therapeutic Development | $2.3M— | $2.3M— | $2.3M-96.4% | —— | —— | |
| Finite Lived Intangible Assets Net by Business | ||||||
| Laboratory Services | $83.3M+21.7% | $62.56M-11.1% | $64.5M-11.1% | $66.47M-10.6% | $68.42M-10.4% | |
| Therapeutic Development | $70.69M— | $70.73M— | $2.27M— | —— | —— | |
| Selling And Marketing Expense by Business | ||||||
| Laboratory Services | $11.58M+52.8% | $10.29M+19.5% | $10.91M+33.1% | $11.58M+52.4% | $7.58M-4.6% | |
| Therapeutic Development | $0— | $5K— | $0— | $0— | $0— | |
| Total Assets by Business | ||||||
| Laboratory Services | $1.05B-6.2% | $1.1B-3.1% | $1.08B-5.4% | $1.11B-2.8% | $1.12B-2.1% | |
| Therapeutic Development | $109.14M+22.8% | $117.15M+31.9% | $131.14M+48.5% | $88.66M-0.1% | $88.9M-0.3% | |
| Investment Income Interest by Business | ||||||
| Laboratory Services | $8.65M+7.9% | $6.94M-14.6% | $7.87M-2.7% | $8.09M+5.0% | $8.02M+8.6% | |
| Therapeutic Development | $0— | $0— | $0— | $0— | $0— | |
| Research And Development Expense by Business | ||||||
| Laboratory Services | $6.46M+31.0% | $6.12M+34.4% | $5.15M+12.1% | $5.44M+11.8% | $4.93M+17.4% | |
| Therapeutic Development | $4.18M+4.7% | $4.88M+17.6% | $5.46M+51.5% | $4.71M+4.8% | $3.99M+17.7% | |
| General And Administrative Expense by Business | ||||||
| Laboratory Services | $20.05M-2.8% | $21.66M+9.2% | $18.53M+13.9% | $21.97M+32.5% | $20.62M+23.5% | |
| Therapeutic Development | $357K+36.8% | $139K-52.4% | $678K+218% | $170K-31.7% | $261K+50.0% | |
| D&A by Business | ||||||
| Laboratory Services | $5.86M+1.8% | $5.98M-0.7% | $5.93M+3.1% | $5.89M-1.5% | $5.76M-11.3% | |
| Therapeutic Development | $143K-12.8% | $132K-22.8% | $110K-34.9% | $165K-5.2% | $164K-5.7% | |
| Allocated Share Based Compensation Expense by Business | ||||||
| Laboratory Services | $7.64M-10.5% | $7.29M-15.0% | $7.72M-14.8% | $8.03M-13.5% | $8.53M-15.0% | |
| Therapeutic Development | $2.25M+11.5% | $1.99M+8.3% | $2M+7.3% | $2.01M-14.5% | $2.02M+36.3% | |
| Finite Lived Intangible Assets Accumulated Amortization by Business | ||||||
| Laboratory Services | $27.28M+31.7% | $25.63M+34.4% | $23.99M+37.2% | $22.35M+41.2% | $20.71M+45.8% | |
| Therapeutic Development | $96K— | $64K— | $32K— | —— | —— | |
| Goodwill by Business | ||||||
| Laboratory Services | $31.38M— | —— | —— | —— | —— | |
| Therapeutic Development | $22.35M+1.1% | $25.08M+13.7% | $25.08M+13.7% | $22.1M+0.2% | $22.1M+0.2% | |
| Revenue by Geography | ||||||
| Non Us | $6.03M+7.0% | $8.43M+37.3% | $6.46M+7.0% | $5.6M-18.1% | $5.64M-15.0% | |
| Other Countries | $3.47M+14.8% | $3.67M+28.1% | $3.33M+2.4% | $3.19M-26.8% | $3.03M+19.6% | |
| PP&E (Net) by Geography | ||||||
| Non Us | $6.16M-4.7% | $6.3M-3.9% | $6.4M+27.5% | $6.56M+40.9% | $6.46M+41.8% | |
| Other Countries | $1.55M-11.7% | $1.61M-17.2% | $1.69M+1,104% | $1.75M— | $1.76M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Fulgent Genetics, Inc. break its business down?
- Fulgent Genetics, Inc. (FLGT) reports revenue by business across 2 parts — Laboratory Services and Therapeutic Development. Each is extracted from the segment footnotes and tracked over time.
- Where does Fulgent Genetics, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Fulgent Genetics, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
